Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Charles D. Webb"'
Autor:
Howard A. Burris, David R. Spigel, F. Anthony Greco, Tarek Mekhail, Terence J. Hadley, Charles D. Webb, John D. Hainsworth, David M. Waterhouse
Publikováno v:
Cancer investigation. 35(8)
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 I
Autor:
Dana S. Thompson, Dianna Shipley, Charles D. Webb, John D. Hainsworth, William Charles Penley, David M. Waterhouse, F. Anthony Greco
Publikováno v:
Cancer Investigation. 31:323-329
Purpose: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Methods: Patients with advanced RCC and ≤1 previous targeted therapy were treated. Results: Maximum tolerated doses were sorafenib 200 mg P
Autor:
Jeffrey R. Infante, Lowell L. Hart, F. Anthony Greco, David R. Spigel, Victor G. Gian, Charles D. Webb, Martin J. Bury, David M. Waterhouse, Dianna Shipley, Howard A. Burris, John D. Hainsworth, John D. Zubkus
Publikováno v:
Lung Cancer. 78:70-75
Background Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-lin
Autor:
F. Anthony Greco, Charles D. Webb, James A. Reeves, Elizabeth R. Vazquez, Howard A. Burris, Roger Inhorn, David R. Spigel, James R. Rubinsak, Dana S. Thompson, John D. Hainsworth, Cassie M. Lane
Publikováno v:
Clinical Lung Cancer. 11:198-203
Background Targeting epidermal growth factor receptors (EGFRs) has been a novel strategy in treating non–small-cell lung cancer (NSCLC). This multicenter, community-based trial was designed to examine the role of cetuximab in combination with a non
Autor:
Denise A. Yardley, David R. Spigel, Jeffrey R. Infante, Howard A. Burris, John D. Hainsworth, Charles D. Webb, C. Farley, F. Anthony Greco
Publikováno v:
Clinical Breast Cancer. 9:23-28
Background The combinations of trastuzumab/docetaxel and trastuzumab/vinorelbine are highly active in the treatment of patients with HER2-positive metastatic breast cancer (MBC). We investigated the feasibility and safety of a 3-drug combination of t
Autor:
J. R. Gray, F. Anthony Greco, Howard A. Burris, Michel E. Kuzur, David R. Spigel, Denise A. Yardley, Dianna Shipley, John D. Hainsworth, Jitendra G. Gandhi, D. S. Thompson, Charles D. Webb, Asim Pati
Publikováno v:
Clinical Lung Cancer. 8:483-487
PURPOSE This prospective randomized study compared overall survival (OS) in patients with previously untreated advanced non–small-cell lung cancer (NSCLC) when treated with the platinum agent–based triple drug combination of paclitaxel/carboplati
Publikováno v:
Southern Journal of Applied Forestry. 24:176-185
The accuracy of ten growth and yie ld models for Southern Appalachian upland hardwood forests and southern bot tomlandforests was evaluated. In technical appl icat ions, accuracy is the composi te both bias (average error) andprecis ion. Resul ts ind
Autor:
Denise A. Yardley, David R. Spigel, F. Anthony Greco, David M. Waterhouse, Charles D. Webb, Tiffanie M. Markus, Howard A. Burris, Mark Mainwaring, John D. Hainsworth
Publikováno v:
Clinical breast cancer. 9(4)
Background Inhibition of the platelet-derived growth factor receptor (PDGFR) might improve the efficacy of chemotherapy by lowering interstitial tumor pressure and allowing increased tumor penetration by cytotoxic agents. In this phase II trial, we a
Autor:
James A. Butts, Howard A. Burris, Sharlene Litchy, F. Anthony Greco, Joan B. Erland, Charles D. Webb, John H. Barton, John D. Hainsworth, Charles Scott, J. R. Gray, Dana S. Thompson, Gerry Ann Houston
Publikováno v:
Cancer. 95(6)
BACKGROUND The authors compared the toxicity, response rate, and progression free survival of four chemotherapy regimens for patients with advanced (Stage IIIB and IV) nonsmall cell lung carcinoma. METHODS A total of 267 patients entered this randomi
Autor:
Scott D. Lunin, Teresa A. Coleman, Karen Dewar, Patricia Pimental, David Wright, Lori Steelman, James Essell, Charles D. Webb, Robert M. Langdon, Ian Flinn, Donald K Strickland, Nina D. Wagner-Johnston, Mike Marris, Nadim F. Nimeh, Charles M. Farber, Patrick Kelly, Scott A. Tetreault
Publikováno v:
Journal of Clinical Oncology. 32:TPS8619-TPS8619
TPS8619 Background: Phosphoinositide 3-kinase (PI3K)-δ,γ isoforms are preferentially expressed in leukocytes, have significant roles in normal B and T cell function, and are central to the growth a...